Although chronic HBV infection is the leading cause of chronic liver disease and death worldwide, there are substantial differences in its clinical courses regarding prevalence, mode of transmission, characteristics of each phase, responses to antiviral therapy, and development of cirrhosis and hepatocellular carcinoma, according to geographical areas (Asia versus Western Europe and North America versus Africa). Furthermore, the clinical course in infected individuals depends on a complex interplay among various factors including viral, host, environmental and other factors. Recently, understanding of molecular characteristics of the prevailing HBV genotypes, frequently accompanied mutations and their clinical implications might explain these geographical differences more pertinently. Hence, in this article, we review the global epidemiology and the natural history of HBV infection, with emphasis on summarizing the different HBV genotypes according to regions.
References
1.
LokA.S., McMahonB.J.Chronic hepatitis B. Hepatology2007; 45: 507–539.
2.
PerzJ.F., ArmstrongG.L., FarringtonL.A., HutinY.J., BellB.P.The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol2006; 45: 529–538.
3.
LavanchyD.Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat2004; 11: 97–107.
4.
FattovichG., BortolottiF., DonatoF.Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol2008; 48: 335–352.
5.
HoffmannC.J., ThioC.L.Clinical implications of HIV and hepatitis B co-infection in Asia and Africa. Lancet Infect Dis2007; 7: 402–409.
6.
ParkN.H., ChungY.H., LeeH.S.Impacts of vaccination on hepatitis B viral infections in Korea over a 25-year period. Intervirology2010; 53: 20–28.
7.
MaynardJ.E.Hepatitis B: global importance and need for control. Vaccine1990; 8 Suppl: S18–20.
8.
AlterM.J., HadlerS.C., MargolisH.S.The changing epidemiology of hepatitis B in the United States. Need for alternative vaccination strategies. JAMA1990; 263: 1218–1222.
9.
LaiC.L., YuenM.F.The natural history of chronic hepatitis B. J Viral Hepat2007; 14Suppl 1: 6–10.
10.
McMahonB.J.The influence of hepatitis B virus genotype and subgenotype on the natural history of chronic hepatitis B. Hepatol Int2009; 3: 334–342.
11.
OkadaK., KamiyamaI., InomataM., ImaiM., MiyakawaY.E antigen and anti-e in the serum of asymptomatic carrier mothers as indicators of positive and negative transmission of hepatitis B virus to their infants. N Engl J Med1976; 294: 746–749.
12.
BeasleyR.P., HwangL.Y., LeeG.C.Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. Lancet1983; 2: 1099–1102.
13.
LiX.M., ShiM.F., YangY.B.Effect of hepatitis B immunoglobulin on interruption of HBV intrauterine infection. World J Gastroenterol2004; 10: 3215–3217.
14.
BurkR.D., HwangL.Y., HoG.Y., ShafritzD.A., BeasleyR.P.Outcome of perinatal hepatitis B virus exposure is dependent on maternal virus load. J Infect Dis1994; 170: 1418–1423.
15.
ThompsonN.D., PerzJ.F., MoormanA.C., HolmbergS.D.Nonhospital health care-associated hepatitis B and C virus transmission: United States, 1998–2008. Ann Intern Med2009; 150: 33–39.
16.
HadziyannisS.Natural history of chronic hepatitis B in Euro-Mediterranean and African Countries. J Hepatol2011; 55: 183–191.
17.
WhittleH., InskipH., BradleyA.K.The pattern of childhood hepatitis B infection in two Gambian villages. J Infect Dis1990; 161: 1112–1115.
18.
AllainJ.P., CandottiD., SoldanK.The risk of hepatitis B virus infection by transfusion in Kumasi, Ghana. Blood2003; 101: 2419–2425.
19.
RoingeardP., DioufA., SankaleJ.L.Perinatal transmission of hepatitis B virus in Senegal, west Africa. Viral Immunol1993; 6: 65–73.
20.
MartinsonF.E., WeigleK.A., RoyceR.A., WeberD.J., SuchindranC.M., LemonS.M.Risk factors for horizontal transmission of hepatitis B virus in a rural district in Ghana. Am J Epidemiol1998; 147: 478–487.
21.
BeasleyR.P., HwangL.Y., LinC.C.Incidence of hepatitis B virus infections in preschool children in Taiwan. J Infect Dis1982; 146: 198–204.
22.
McMahonB.J., AlwardW.L., HallD.B.Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis1985; 151: 599–603.
23.
MastE.E., AlterM.J., MargolisH.S.Strategies to prevent and control hepatitis B and C virus infections: a global perspective. Vaccine1999; 17: 1730–1733.
24.
AlterM.J.Epidemiology of hepatitis B in Europe and worldwide. J Hepatol2003; 39Suppl 1: S64–S69.
25.
LivingstonS.E., SimonettiJ.P., BulkowL.R.Clearance of hepatitis B e antigen in patients with chronic hepatitis B and genotypes A, B, C, D, and F. Gastroenterology2007; 133: 1452–1457.
26.
WasleyA., GrytdalS., GallagherK.Surveillance for acute viral hepatitis – United States, 2006. MMWR Surveill Summ2008; 57: 1–24.
27.
Des JarlaisD.C., DiazT., PerlisT.Variability in the incidence of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus infection among young injecting drug users in New York City. Am J Epidemiol2003; 157: 467–471.
28.
SchaeferS.Hepatitis B virus taxonomy and hepatitis B virus genotypes. World J Gastroenterol2007; 13: 14–21.
29.
NorderH., CourouceA.M., MagniusL.O.Complete genomes, phylogenetic relatedness, and structural proteins of six strains of the hepatitis B virus, four of which represent two new genotypes. Virology1994; 198: 489–503.
30.
StuyverL., De GendtS., Van GeytC.A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness. J Gen Virol2000; 81: 67–74.
31.
LinC.L., KaoJ.H.The clinical implications of hepatitis B virus genotype: Recent advances. J Gastroenterol Hepatol2011; 26Suppl 1: 123–130.
32.
KaoJ.H.Hepatitis B viral genotypes: clinical relevance and molecular characteristics. J Gastroenterol Hepatol2002; 17: 643–650.
33.
KramvisA., KewM.C.Relationship of genotypes of hepatitis B virus to mutations, disease progression and response to antiviral therapy. J Viral Hepat2005; 12: 456–464.
34.
KewM.C., KramvisA., YuM.C., ArakawaK., HodkinsonJ.Increased hepatocarcinogenic potential of hepatitis B virus genotype A in Bantu-speaking sub-Saharan Africans. J Med Virol2005; 75: 513–521.
35.
KramvisA., RestorpK., NorderH., BothaJ.F., MagniusL.O., KewM.C.Full genome analysis of hepatitis B virus genotype E strains from South-Western Africa and Madagascar reveals low genetic variability. J Med Virol2005; 77: 47–52.
36.
KewM.C., KramvisA., YuM.C., ArakawaK., HodkinsonJ.Increased hepatocarcinogenic potential of hepatitis B virus genotype A in Bantu-speaking sub-saharan Africans. J Med Virol2005; 75: 513–521.
37.
KramvisA., KewM.C.Epidemiology of hepatitis B virus in Africa, its genotypes and clinical associations of genotypes. Hepatol Res2007; 37: S9–S19.
38.
TanakaY., HasegawaI., KatoT.A case-control study for differences among hepatitis B virus infections of genotypes A (subtypes Aa and Ae) and D. Hepatology2004; 40: 747–755.
39.
RevillP.A., LittlejohnM., AyresA.Identification of a novel hepatitis B virus precore/core deletion mutant in HIV/hepatitis B virus co-infected individuals. AIDS2007; 21: 1701–1710.
40.
KurbanovF., TanakaY., FujiwaraK.A new subtype (subgenotype) Ac (A3) of hepatitis B virus and recombination between genotypes A and E in Cameroon. J Gen Virol2005; 86: 2047–2056.
41.
SakamotoT., TanakaY., SimonettiJ.Classification of hepatitis B virus genotype B into 2 major types based on characterization of a novel subgenotype in Arctic indigenous populations. J Infect Dis2007; 196: 1487–1492.
42.
KobayashiM., SuzukiF., AkutaN.Virological differences between patients infected with subtypes Ba and Bj of hepatitis B virus genotype B. J Gastroenterol Hepatol2005; 20: 570–576.
43.
SugauchiF., OritoE., IchidaT.Epidemiologic and virologic characteristics of hepatitis B virus genotype B having the recombination with genotype C. Gastroenterology2003; 124: 925–932.
44.
SugauchiF., OritoE., IchidaT.Epidemiologic and virologic characteristics of hepatitis B virus genotype B having the recombination with genotype C. Gastroenterology2003; 124: 925–932.
45.
OzasaA., TanakaY., OritoE.Influence of genotypes and precore mutations on fulminant or chronic outcome of acute hepatitis B virus infection. Hepatology2006; 44: 326–334.
46.
ChuC.M., LiawY.F.Genotype C hepatitis B virus infection is associated with a higher risk of reactivation of hepatitis B and progression to cirrhosis than genotype B: a longitudinal study of hepatitis B e antigen-positive patients with normal aminotransferase levels at baseline. J Hepatol2005; 43: 411–417.
47.
ChanH.L., TsuiS.K., TseC.H.Epidemiological and virological characteristics of 2 subgroups of hepatitis B virus genotype C. J Infect Dis2005; 191: 2022–2032.
48.
HuyT.T., UshijimaH., QuangV.X.Genotype C of hepatitis B virus can be classified into at least two subgroups. J Gen Virol2004; 85: 283–292.
49.
AhnS.H., YuenL., RevillP.Clarification required for the definition of hepatitis B virus subgenotypes C1 and C2. Intervirology2009; 52: 321–322.
50.
SakamotoT., TanakaY., OritoE.Novel subtypes (subgenotypes) of hepatitis B virus genotypes B and C among chronic liver disease patients in the Philippines. J Gen Virol2006; 87: 1873–1882.
51.
ChanH.L., TseC.H., MoF.High viral load and hepatitis B virus subgenotype Ce are associated with increased risk of hepatocellular carcinoma. J Clin Oncol2008; 26: 177–182.
52.
AhnS.H., YuenL., HanK.H.Molecular and clinical characteristics of hepatitis B virus in Korea. J Med Virol2010; 82: 1126–1134.
53.
ChanH.L., WongG.L., TseC.H.Hepatitis B virus genotype C is associated with more severe liver fibrosis than genotype B. Clin Gastroenterol Hepatol2009; 7: 1361–1366.
54.
ZhuL., TseC.H., WongV.W., ChimA.M., LeungK.S., ChanH.L.A complete genomic analysis of hepatitis B virus genotypes and mutations in HBeAg-negative chronic hepatitis B in China. J Viral Hepat2008; 15: 449–458.
55.
WestlandC., DelaneyW., YangH.Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1. Gastroenterology2003; 125: 107–116.
56.
GrandjacquesC., PradatP., StuyverL.Rapid detection of genotypes and mutations in the pre-core promoter and the pre-core region of hepatitis B virus genome: correlation with viral persistence and disease severity. J Hepatol2000; 33: 430–439.
57.
ModiA.A., FeldJ.J.Viral hepatitis and HIV in Africa. AIDS Rev2007; 9: 25–39.
58.
ZacharakisG.H., KoskinasJ., KotsiouS.Natural history of chronic HBV infection: a cohort study with up to 12 years follow-up in North Greece (part of the Interreg I-II/ EC-project). J Med Virol2005; 77: 173–179.
59.
EchevarriáJ.M., LeonP.Hepatitis B virus genotypes identified by a Line Probe Assay (LiPA) among chronic carriers from Spain. Enferm Infecc Microbiol Clin2004; 22: 452–454.
60.
SuzukiS., SugauchiF., OritoE.Distribution of hepatitis B virus (HBV) genotypes among HBV carriers in the Cote d'Ivoire: complete genome sequence and phylogenetic relatedness of HBV genotype E. J Med Virol2003; 69: 459–465.
61.
TeH.S., JensenD.M.Epidemiology of hepatitis B and C viruses: a global overview. Clin Liver Dis2010; 14: 1–21.
62.
Arauz-RuizP., NorderH., RobertsonB.H., MagniusL.O.Genotype H: a new Amerindian genotype of hepatitis B virus revealed in Central America. J Gen Virol2002; 83: 2059–2073.
63.
KatoH., OritoE., GishR.G.Hepatitis B e antigen in sera from individuals infected with hepatitis B virus of genotype G. Hepatology2002; 35: 922–929.
64.
DevesaM., PujolF.H.Hepatitis B virus genetic diversity in Latin America. Virus Res2007; 127: 177–184.
65.
HuyT.T.T., TrinhT.N., AbeK.New complex recombinant genotype of hepatitis B virus identified in Vietnam. J Virol2008; 82: 5657–5663.
66.
HannounC., NorderH., LindhM.An aberrant genotype revealed in recombinant hepatitis B virus strains from Vietnam. J Gen Virol2000; 81: 2267–2272.
67.
KurbanovF., TanakaY., KramvisA., SimmondsP., MizokamiM.When should “I” consider a new hepatitis B virus genotype?J Virol2008; 82: 8241–8242.
68.
TatematsuK., TanakaY., KurbanovF.A genetic variant of hepatitis B virus divergent from known human and ape genotypes isolated from a Japanese patient and provisionally assigned to new genotype J. J Virol2009; 83: 10538–10547.
69.
EASL.EASL International Consensus Conference on Hepatitis B. 13–14 September, 2002: Geneva, Switzerland. Consensus statement (short version). J Hepatol2003; 38: 533–540.
70.
ChangM.H., HwangL.Y., HsuH.C., LeeC.Y., BeasleyR.P.Prospective study of asymptomatic HBsAg carrier children infected in the perinatal period: clinical and liver histologic studies. Hepatology1988; 8: 374–377.
71.
LiawY.F., ChuC.M., LinD.Y., SheenI.S., YangC.Y., HuangM.J.Age-specific prevalence and significance of hepatitis B e antigen and antibody in chronic hepatitis B virus infection in Taiwan: a comparison among asymptomatic carriers, chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. J Med Virol1984; 13: 385–391.
72.
MilichD.R., JonesJ.E., HughesJ.L., PriceJ., RaneyA.K., McLachlanA.Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero?Proc Natl Acad Sci U S A1990; 87: 6599–6603.
73.
HsuH.Y., ChangM.H., HsiehK.H.Cellular immune response to HBcAg in mother-to-infant transmission of hepatitis B virus. Hepatology1992; 15: 770–776.
74.
ChuC.M., HungS., LinJ., TaiD., LiawY.Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels. Am J Med2004; 116: 829–834.
75.
McMahonB.J.The natural history of chronic hepatitis B virus infection. Hepatology2009; 49: S45–S55.
76.
VisvanathanK., SkinnerN.A., ThompsonA.J.Regulation of Toll-like receptor-2 expression in chronic hepatitis B by the precore protein. Hepatology2007; 45: 102–110.
77.
LangT., LoC., SkinnerN., LocarniniS., VisvanathanK., MansellA.The hepatitis B e antigen (HBeAg) targets and suppresses activation of the Toll-like receptor signaling pathway. J Hepatol2011; 55: 762–769.
78.
MaruyamaT., IinoS., KoikeK., YasudaK., MilichD.R.Serology of acute exacerbation in chronic hepatitis B virus infection. Gastroenterology1993; 105: 1141–1151.
79.
HsuH.C., SuI.J., LaiM.Y.Biologic and prognostic significance of hepatocyte hepatitis B core antigen expressions in the natural course of chronic hepatitis B virus infection. J Hepatol1987; 5: 45–50.
80.
WenW.H., ChangM.H., HsuH.Y., NiY.H., ChenH.L.The development of hepatocellular carcinoma among prospectively followed children with chronic hepatitis B virus infection. J Pediatr2004; 144: 397–399.
81.
ChangM.H., HsuH.Y., HsuH.C., NiY.H., ChenJ.S., ChenD.S.The significance of spontaneous hepatitis B e antigen seroconversion in childhood: with special emphasis on the clearance of hepatitis B e antigen before 3 years of age. Hepatology1995; 22: 1387–1392.
82.
ChuC.J., HussainM., LokA.S.Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. Gastroenterology2002; 122: 1756–1762.
83.
YuenM.F., SablonE., YuanH.Significance of hepatitis B genotype in acute exacerbation, HBeAg seroconversion, cirrhosis-related complications, and hepatocellular carcinoma. Hepatology2003; 37: 562–567.
84.
SongE., DusheikoG.M., BowyerS., KewM.C.Hepatitis B virus replication in southern Africa blacks with HBsAg-positive hepatocellular carcinoma. Hepatology1984; 4: 608–610.
85.
BothaJ.F., RitchieM.J., DusheikoG.M., MoutonH.W., KewM.C.Hepatitis B virus carrier state in black children in Ovamboland: role of perinatal and horizontal infection. Lancet1984; 1: 1210–1212.
86.
AhnS.H., KramvisA., KawaiS.Sequence variation upstream of precore translation initiation codon reduces hepatitis B virus e antigen production. Gastroenterology2003; 125: 1370–1378.
87.
YuenM.F., LaiC.L.Hepatitis B virus genotypes: natural history and implications for treatment. Expert Rev Gastroenterol Hepatol2007; 1: 321–328.
88.
McMillanJ.S., BowdenD.S., AngusP.W., McCaughanG.W., LocarniniS.A.Mutations in the hepatitis B virus precore/ core gene and core promoter in patients with severe recurrent disease following liver transplantation. Hepatology1996; 24: 1371–1378.
89.
Rodriguez-FriasF., ButiM., JardiR.Hepatitis B virus infection: precore mutants and its relation to viral genotypes and core mutations. Hepatology1995; 22: 1641–1647.
90.
AlwardW.L., McMahonB.J., HallD.B., HeywardW.L., FrancisD.P., BenderT.R.The long-term serological course of asymptomatic hepatitis B virus carriers and the development of primary hepatocellular carcinoma. J Infect Dis1985; 151: 604–609.
91.
LiawY.F., SheenI.S., ChenT.J., ChuC.M., PaoC.C.Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: a prospective study. Hepatology1991; 13: 627–631.
92.
YuenM.F., WongD.K., FungJ.HBsAg Seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology2008; 135: 1192–1199.
93.
FunkM.L., RosenbergD.M., LokA.S.World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants. J Viral Hepat2002; 9: 52–61.
94.
ChenC.J., YangH.I., SuJ.Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA2006; 295: 65–73.
95.
PapatheodoridisG.V., ManesisE., HadziyannisS.J.The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol2001; 34: 306–313.
96.
HadziyannisS.J., VassilopoulosD.Hepatitis B e antigen-negative chronic hepatitis B. Hepatology2001; 34: 617–624.
97.
LamperticoP., ViganoM., ManentiE., IavaroneM., SablonE., ColomboM.Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology2007; 133: 1445–1451.
98.
Arauz-RuizP., NorderH., VisonaK.A., MagniusL.O.Genotype F prevails in HBV infected patients of Hispanic origin in Central America and may carry the precore stop mutant. J Med Virol1997; 51: 305–312.
99.
LindhM., AnderssonA.S., GusdalA.Genotypes, nt 1858 variants, and geographic origin of hepatitis B virus–large-scale analysis using a new genotyping method. J Infect Dis1997; 175: 1285–1293.
100.
DimouE., RaptiI., KostamenaA., LarasA., HadziyannisS.Development of precore and basic core promoter HBV mutations in chronic hepatitis B genotypes D and A. A prospecitve study in a Caucasian population. Hepatology2009; 50Suppl 4: 983A.
101.
AhnS.H., ParkY.N., ParkJ.Y.Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance. J Hepatol2005; 42: 188–194.
102.
McMahonB.J., HolckP., BulkowL., SnowballM.Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus. Ann Intern Med2001; 135: 759–768.
103.
ChuC.M., LiawY.F.HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up. Hepatology2007; 45: 1187–1192.
104.
Sánchez-TapiasJ.M., CostaJ., MasA., BrugueraM., RodesJ.Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients. Gastroenterology2002; 123: 1848–1856.
105.
LiawY.F., BrunettoM.R., HadziyannisS.The natural history of chronic HBV infection and geographical differences. Antivir Ther2010; 15Suppl 3: 25–33.
106.
SimonettiJ., BulkowL., McMahonB.J.Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus. Hepatology2010; 51: 1531–1537.
107.
BahnA., GernerP., MartinU., BortolottiF., WirthS.Detection of different viral strains of hepatitis B virus in chronically infected children after seroconversion from HBsAg to anti-HBs indicating viral persistence. J Hepatol1997; 27: 973–978.
108.
KomoriM., YukiN., NagaokaT.Long-term clinical impact of occult hepatitis B virus infection in chronic hepatitis B patients. J Hepatol2001; 35: 798–804.
109.
LoriotM.A., MarcellinP., WalkerF.Persistence of hepatitis B virus DNA in serum and liver from patients with chronic hepatitis B after loss of HBsAg. J Hepatol1997; 27: 251–258.
110.
RaimondoG., NavarraG., MondelloS.Occult hepatitis B virus in liver tissue of individuals without hepatic disease. J Hepatol2008; 48: 743–746.
111.
BréchotC., ThiersV., KremsdorfD., NalpasB., PolS., Paterlini-BrechotP.Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely “occult”?Hepatology2001; 34: 194–203.
112.
MinukG.Y., SunD., UhanovaJ.Occult hepatitis B virus infection in a North American community-based population. J Hepatol2005; 42: 480–485.
113.
LokA.S., AkarcaU., GreeneS.Mutations in the pre-core region of hepatitis B virus serve to enhance the stability of the secondary structure of the pre-genome encapsidation signal. Proc Natl Acad Sci U S A1994; 91: 4077–4081.
114.
ChoiJ.W., AhnS.H., ParkJ.Y.Hepatitis B e antigen-negative mutations in the precore and core promoter regions in Korean patients. J Med Virol2009; 81: 594–601.
115.
KimJ.K., ChangH.Y., LeeJ.M.Specific mutations in the enhancer II/core promoter/precore regions of hepatitis B virus subgenotype C2 in Korean patients with hepatocellular carcinoma. J Med Virol2009; 81: 1002–1008.
116.
KewM.C.Hepatitis B virus x protein in the pathogenesis of hepatitis B virus-induced hepatocellular carcinoma. J Gastroenterol Hepatol2011; 26Suppl 1: 144–152.
117.
LinC.L., LiuC.H., ChenW.Association of pre-S deletion mutant of hepatitis B virus with risk of hepatocellular carcinoma. J Gastroenterol Hepatol2007; 22: 1098–1103.
118.
LinC.L., KaoJ.H.The clinical implications of hepatitis B virus genotype: recent advances. J Gastroenterol Hepatol2011; 26Suppl 1: 123–130.
119.
LiuY., ZhongY., ZouZ.Features and clinical implications of hepatitis B virus genotypes and mutations in basal core promoter/precore region in 507 Chinese patients with acute and chronic hepatitis B. J Clin Virol201047: 243–247.
120.
ChenB.F., LiuC.J., JowG.M., ChenP.J., KaoJ.H., ChenD.S.High prevalence and mapping of pre-S deletion in hepatitis B virus carriers with progressive liver diseases. Gastroenterology2006; 130: 1153–1168.
121.
Rodriguez-FriasF., JardiR., ButiM.Hepatitis B virus genotypes and G1896A precore mutation in 486 Spanish patients with acute and chronic HBV infection. J Viral Hepat2006; 13: 343–350.
122.
HsuY.S., ChienR., YehC.Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology2002; 35: 1522–1527.
123.
MannoM., CammC., SchepisF.Natural history of chronic HBV carriers in northern Italy: morbidity and mortality after 30 years. Gastroenterology2004; 127: 756–763.
124.
YuM.W., HsuF.C., SheenI.S.Prospective study of hepatocellular carcinoma and liver cirrhosis in asymptomatic chronic hepatitis B virus carriers. Am J Epidemiol1997; 145: 1039–1047.
125.
IloejeU.H., YangH.I., SuJ., JenC., YouS., ChenC.Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology2006; 130: 678–686.
126.
MazzellaG., SaraccoG., FestiD.Long-term results with interferon therapy in chronic type B hepatitis: a prospective randomized trial. Am J Gastroenterol1999; 94: 2246–2250.
127.
LiawY.F., TaiD.I., ChuC.M., ChenT.J.The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology1988; 8: 493–496.
128.
LinS.M., YuM.L., LeeC.M.Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol2007; 46: 45–52.
129.
JangJ.W., LeeY.C., KimM.S.A 13-year longitudinal study of the impact of double mutations in the core promoter region of hepatitis B virus on HBeAg seroconversion and disease progression in patients with genotype C chronic active hepatitis. J Viral Hepat2007; 14: 169–175.
130.
Moreno-OteroR., Garca-MonznC., Garca-SnchezA., BueyL.G., PajaresJ.M., Di BisceglieA.M.Development of cirrhosis after chronic type B hepatitis: a clinicopathologic and follow-up study of 46 HBeAg-positive asymptomatic patients. Am J Gastroenterol1991; 86: 560–564.
131.
FattovichG., BrolloL., AlbertiA., PontissoP., GiustinaG., RealdiG.Long-term follow-up of anti-HBe-positive chronic active hepatitis B. Hepatology1988; 8: 1651–1654.
132.
BrunettoM.R., OliveriF., RoccaG.Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B e antigen. Hepatology1989; 10: 198–202.
133.
TsukumaH., HiyamaT., TanakaS.Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med1993; 328: 1797–1801.
134.
BeasleyR.P., HwangL.Y., LinC.C., ChienC.S.Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet1981; 2: 1129–1133.
135.
ShermanM., PeltekianK.M., LeeC.Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology1995; 22: 432–438.
136.
VilleneuveJ.P., DesrochersM., Infante-RivardC.A long-term follow-up study of asymptomatic hepatitis B surface antigen-positive carriers in Montreal. Gastroenterology1994; 106: 1000–1005.
137.
BeasleyR.P.Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer1988; 61: 1942–1956.
138.
HanK.H., AhnS.H.How to predict HCC development in patients with chronic B viral liver disease?Intervirology2005; 48: 23–28.
139.
YangH.I., YehS.H., ChenP.J.Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst2008; 100: 1134–1143.
140.
PratesM.D., TorresF.O.A cancer survey in Lourenço Marques, Portuguese East Africa. J Natl Cancer Inst1965; 35: 729–757.
141.
ColomboM., de FranchisR., Del NinnoE.Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med1991; 325: 675–680.
142.
KirkG.D., LesiO.A., MendyM.The Gambia Liver Cancer Study: Infection with hepatitis B and C and the risk of hepatocellular carcinoma in West Africa. Hepatology2004; 39: 211–219.
143.
DragosicsB., FerenciP., HitchmanE., DenkH.Long-term follow-up study of asymptomatic HBsAg-positive voluntary blood donors in Austria: a clinical and histologic evaluation of 242 cases. Hepatology1987; 7: 302–306.
de FranchisR., MeucciG., VecchiM.The natural history of asymptomatic hepatitis B surface antigen carriers. Ann Intern Med1993; 118: 191–194.
146.
BenvegnúL., ChemelloL., NoventaF., FattovichG., PontissoP., AlbertiA.Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis. Cancer1998; 83: 901–909.
147.
FattovichG., PantalenaM., ZagniI., RealdiG., SchalmS.W., ChristensenE.Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. Am J Gastroenterol2002; 97: 2886–2895.
148.
ChenY.C., ChuC., YehC., LiawY.Natural course following the onset of cirrhosis in patients with chronic hepatitis B: a long-term follow-up study. Hepatol Int2007; 1: 267–273.
149.
KobayashiM., IkedaK., HosakaT.Natural history of compensated cirrhosis in the Child-Pugh class A compared between 490 patients with hepatitis C and 167 with B virus infections. J Med Virol2006; 78: 459–465.
150.
LiawY.F., LinD.Y., ChenT.J., ChuC.M.Natural course after the development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Liver1989; 9: 235–241.
151.
BeasleyR.P.Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer1988; 61: 1942–1956.
152.
BahE., ParkinD.M., HallA.J., JackA.D., WhittleH.Cancer in the Gambia: 1988-97. Br J Cancer2001; 84: 1207–1214.
153.
WiegandJ., HasencleverD., TillmannH.L.Should treatment of hepatitis B depend on hepatitis B virus genotypes? A hypothesis generated from an explorative analysis of published evidence. Antivir Ther2008; 13: 211–220.
154.
LauG.K., PiratvisuthT., LuoK.X.Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med2005; 352: 2682–2695.
155.
ErhardtA., BlondinD., HauckK.Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D. Gut2005; 54: 1009–1013.
156.
JanssenH.L., van ZonneveldM., SenturkH.Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet2005; 365: 123–129.
157.
ChanH.L., HuiA.Y., WongV.W., ChimA.M., WongM.L., SungJ.J.Long-term follow-up of peginterferon and lamivudine combination treatment in HBeAg-positive chronic hepatitis B. Hepatology2005; 41: 1357–1364.
158.
ZhaoH., KurbanovF., WanM.B.Genotype B and younger patient age associated with better response to low-dose therapy: a trial with pegylated/nonpegylated interferon-alpha-2b for hepatitis B e antigen-positive patients with chronic hepatitis B in China. Clin Infect Dis2007; 44: 541–548.
159.
LiuC.J., LaiM.Y., ChaoY.C.Interferon alpha-2b with and without ribavirin in the treatment of hepatitis B e antigen-positive chronic hepatitis B: a randomized study. Hepatology2006; 43: 742–749.
160.
ZhangX., ZoulimF., HabersetzerF., XiongS., TrepoC.Analysis of hepatitis B virus genotypes and pre-core region variability during interferon treatment of HBe antigen negative chronic hepatitis B. J Med Virol1996; 48: 8–16.
161.
BoninoF., MarcellinP., LauG.K.Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut2007; 56: 699–705.
162.
FlinkH.J., HansenB.E., HeathcoteE.J.Successful treatment with peginterferon alfa-2b of HBeAg-positive HBV non-responders to standard interferon or lamivudine. Am J Gastroenterol2006; 101: 2523–2529.
163.
HadziyannisS., LauG.K., MarcellinP., PiratvisuthT., CooksleyG., BorinoF.Sustained HBsAg seroconversion in patients with chronic hepatitis B treated with peginterferon alpha-2a (40KD) (Pegasys). J Hepatol2005; 42Suppl 2: 178.
164.
LiuC.J., KaoJ.H.Genetic variability of hepatitis B virus and response to antiviral therapy. Antivir Ther2008; 13: 613–624.
165.
DamerowH., YuenL., WiegandJ.Mutation pattern of lamivudine resistance in relation to hepatitis B genotypes: hepatitis B genotypes differ in their lamivudine resistance associated mutation pattern. J Med Virol2010; 82: 1850–1858.
166.
WarnerN., LocarniniS.The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound. Hepatology2008; 48: 88–98.
167.
LaiM.W., YehC.T.The oncogenic potential of hepatitis B virus rtA181T/ surface truncation mutant. Antivir Ther2008; 13: 875–879.
168.
YuenL., AyresA., LittlejohnM., EdwardsR., LocarniniS.Evolution of the Hepatitis B surface antigen in European and Asian HBV genotypes during the era of antiviral therapy. Hepatol Int2011; 5: 150A.
169.
MunozA., ChenJ.G., EgnerP.A.Predictive power of hepatitis B 1762T/1764A mutations in plasma for hepatocellular carcinoma risk in Qidong, China. Carcinogenesis2011; 32: 860–865.
170.
KuangS.Y., JacksonP.E., WangJ.B.Specific mutations of hepatitis B virus in plasma predict liver cancer development. Proc Natl Acad Sci U S A2004; 101: 3575–3580.
